A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein.

Aimin TangZhifeng ChenKara S CoxHua-Poo SuCheryl CallahanArthur FridmanLan ZhangSangita B PatelPedro J CejasRyan SwoyerSinoeun TouchMichael P CitronDhanasekaran GovindarajanBin LuoMichael EddinsJohn C ReidStephen M SoissonJennifer GalliDai WangZhiyun WenGwendolyn J HeideckerDanilo R CasimiroDaniel J DiStefanoKalpit A Vora

Published in: Nature communications (2019)

Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation of a potent and broadly neutralizing RSV monoclonal antibody derived from a human memory B-cell. This antibody, RB1, is equipotent on RSV A and B subtypes, potently neutralizes a diverse panel of clinical isolates in vitro and demonstrates in vivo protection. It binds to a highly conserved epitope in antigenic site IV of the RSV fusion glycoprotein. RB1 is the parental antibody to MK-1654 which is currently in clinical development for the prevention of RSV infection in infants.

Keyphrases